Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:09 AM
Ignite Modification Date:
2025-12-25 @ 3:09 AM
NCT ID:
NCT00395005
Eligibility Criteria:
Inclusion Criteria:
* During June 2004 and June 2005 who participate the clinical study "Efficacy of Pentoxifylline on Chronic Kidney Disease" (ClinicalTrials.gov Identifier: NCT00155246)and sign the informed consent.
* Chronic kidney disease history \> 3 months, Serum creatinine: 1.1\~6.0 mg/dl in female. 1.3\~6.2 mg/dl in male.
* Initial Random urine protein (mg/dl) /creatinine (mg/dl) ratio \> 0.5
Exclusion Criteria:
* History of allergy to pentoxifylline;
* females are nursing or pregnant;
* Obstructive uropathy;
* Unable to stop chronic immunosuppressive therapy, NSAID;
* Congestive heart failure (New York Heart Association functional class III or IV);
* Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form;
* Cerebral hemorrhage within the past 6 months prior to signing the informed consent form;
* Retinal hemorrhage within the past 6 months prior to signing the informed consent form;
* Known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular hypertension, pheochromocytoma);
* Severe uncontrolled hypertension with SBP \> 220 mmHg and/or DBP \> 115 mmHg;
* Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST \> 2 times the upper limit of the normal range;
* Biliary obstructive disorders (e.g. cholestasis);
* Active malignancy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
70 Years
Study:
NCT00395005
Study Brief:
Protocol Section:
NCT00395005